Pharmacologic characterization of the antiinflammatory properties of a new dual inhibitor of lipoxygenase and cyclooxygenase

M. J. DiMartino, D. E. Griswold, B. A. Berkowitz, George Poste, N. Hanna

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

SK&F 86002 [6-(4-fluorophenyl)2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole], a dual inhibitor of arachidonic acid metabolism, administered orally to rats prevented the development of carrageenan-induced edema, immune- and nonimmune-mediated inflammation of adjuvant-induced arthritis (AA) and reduced established inflammation in AA and collagen type II-induced arthritis. A similar profile of activity was observed following treatment with the cyclooxygenase inhibitor, indomethacin. However, unlike other nonsteroidal antiinflammatory drugs, SK&F 86002 exhibited antiinflammatory activity in inflammation models that are insensitive to cyclooxygenase inhibitors such as the established inflammation in carrageenan-induced edema and the edema induced by arachidonic acid and platelet activating factor. Moreover, SK&F 86002, but not indomethacin, inhibited the immune-mediated inflammatory responses evoked in sensitized animals by challenge with purified protein derivative. In addition, SK&F 86002 produced dose-related analgesia in mice, which was not reversed by the narcotic antagonist, naltexone. SK&F 86002 thus represents an orally active antiarthritic and analgesic compound with novel antiinflammatory properties.

Original languageEnglish (US)
Pages (from-to)113-123
Number of pages11
JournalAgents and Actions
Volume20
Issue number1-2
DOIs
StatePublished - Feb 1987
Externally publishedYes

Fingerprint

Lipoxygenase Inhibitors
Cyclooxygenase Inhibitors
Experimental Arthritis
Anti-Inflammatory Agents
Carrageenan
Inflammation
Arachidonic Acid
Indomethacin
Edema
Narcotic Antagonists
Collagen Type II
Platelet Activating Factor
Metabolism
Analgesics
Rats
Animals
Analgesia
Derivatives
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)

Cite this

Pharmacologic characterization of the antiinflammatory properties of a new dual inhibitor of lipoxygenase and cyclooxygenase. / DiMartino, M. J.; Griswold, D. E.; Berkowitz, B. A.; Poste, George; Hanna, N.

In: Agents and Actions, Vol. 20, No. 1-2, 02.1987, p. 113-123.

Research output: Contribution to journalArticle

DiMartino, M. J. ; Griswold, D. E. ; Berkowitz, B. A. ; Poste, George ; Hanna, N. / Pharmacologic characterization of the antiinflammatory properties of a new dual inhibitor of lipoxygenase and cyclooxygenase. In: Agents and Actions. 1987 ; Vol. 20, No. 1-2. pp. 113-123.
@article{e7ae30790aa54bfaa2e836c2946e7cbc,
title = "Pharmacologic characterization of the antiinflammatory properties of a new dual inhibitor of lipoxygenase and cyclooxygenase",
abstract = "SK&F 86002 [6-(4-fluorophenyl)2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole], a dual inhibitor of arachidonic acid metabolism, administered orally to rats prevented the development of carrageenan-induced edema, immune- and nonimmune-mediated inflammation of adjuvant-induced arthritis (AA) and reduced established inflammation in AA and collagen type II-induced arthritis. A similar profile of activity was observed following treatment with the cyclooxygenase inhibitor, indomethacin. However, unlike other nonsteroidal antiinflammatory drugs, SK&F 86002 exhibited antiinflammatory activity in inflammation models that are insensitive to cyclooxygenase inhibitors such as the established inflammation in carrageenan-induced edema and the edema induced by arachidonic acid and platelet activating factor. Moreover, SK&F 86002, but not indomethacin, inhibited the immune-mediated inflammatory responses evoked in sensitized animals by challenge with purified protein derivative. In addition, SK&F 86002 produced dose-related analgesia in mice, which was not reversed by the narcotic antagonist, naltexone. SK&F 86002 thus represents an orally active antiarthritic and analgesic compound with novel antiinflammatory properties.",
author = "DiMartino, {M. J.} and Griswold, {D. E.} and Berkowitz, {B. A.} and George Poste and N. Hanna",
year = "1987",
month = "2",
doi = "10.1007/BF01965633",
language = "English (US)",
volume = "20",
pages = "113--123",
journal = "Inflammation Research",
issn = "1023-3830",
publisher = "Birkhauser Verlag Basel",
number = "1-2",

}

TY - JOUR

T1 - Pharmacologic characterization of the antiinflammatory properties of a new dual inhibitor of lipoxygenase and cyclooxygenase

AU - DiMartino, M. J.

AU - Griswold, D. E.

AU - Berkowitz, B. A.

AU - Poste, George

AU - Hanna, N.

PY - 1987/2

Y1 - 1987/2

N2 - SK&F 86002 [6-(4-fluorophenyl)2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole], a dual inhibitor of arachidonic acid metabolism, administered orally to rats prevented the development of carrageenan-induced edema, immune- and nonimmune-mediated inflammation of adjuvant-induced arthritis (AA) and reduced established inflammation in AA and collagen type II-induced arthritis. A similar profile of activity was observed following treatment with the cyclooxygenase inhibitor, indomethacin. However, unlike other nonsteroidal antiinflammatory drugs, SK&F 86002 exhibited antiinflammatory activity in inflammation models that are insensitive to cyclooxygenase inhibitors such as the established inflammation in carrageenan-induced edema and the edema induced by arachidonic acid and platelet activating factor. Moreover, SK&F 86002, but not indomethacin, inhibited the immune-mediated inflammatory responses evoked in sensitized animals by challenge with purified protein derivative. In addition, SK&F 86002 produced dose-related analgesia in mice, which was not reversed by the narcotic antagonist, naltexone. SK&F 86002 thus represents an orally active antiarthritic and analgesic compound with novel antiinflammatory properties.

AB - SK&F 86002 [6-(4-fluorophenyl)2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole], a dual inhibitor of arachidonic acid metabolism, administered orally to rats prevented the development of carrageenan-induced edema, immune- and nonimmune-mediated inflammation of adjuvant-induced arthritis (AA) and reduced established inflammation in AA and collagen type II-induced arthritis. A similar profile of activity was observed following treatment with the cyclooxygenase inhibitor, indomethacin. However, unlike other nonsteroidal antiinflammatory drugs, SK&F 86002 exhibited antiinflammatory activity in inflammation models that are insensitive to cyclooxygenase inhibitors such as the established inflammation in carrageenan-induced edema and the edema induced by arachidonic acid and platelet activating factor. Moreover, SK&F 86002, but not indomethacin, inhibited the immune-mediated inflammatory responses evoked in sensitized animals by challenge with purified protein derivative. In addition, SK&F 86002 produced dose-related analgesia in mice, which was not reversed by the narcotic antagonist, naltexone. SK&F 86002 thus represents an orally active antiarthritic and analgesic compound with novel antiinflammatory properties.

UR - http://www.scopus.com/inward/record.url?scp=0023149076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023149076&partnerID=8YFLogxK

U2 - 10.1007/BF01965633

DO - 10.1007/BF01965633

M3 - Article

C2 - 3107354

AN - SCOPUS:0023149076

VL - 20

SP - 113

EP - 123

JO - Inflammation Research

JF - Inflammation Research

SN - 1023-3830

IS - 1-2

ER -